Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
RUTHERFORD, N.J., Aug. 13, 2013 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX), a diagnostics company focused on developing genomic-based, oncology tests and services, today announced the pricing of its public offering of 1,500,000 shares of its common stock at a price to the public of $10.00 per share. The gross proceeds to Cancer Genetics from the public offering are expected to be $15,000,000, before underwriting discounts and commissions and other offering expenses payable by Cancer Genetics.
Help employers find you! Check out all the jobs and post your resume.
